split-banner-image

IBIS-II

Closed

ANZ 02P2: IBIS-II (Prevention)

BCT Study Chair:

Nicholas Zdenkowski

An international multi-centre trial of anastrozole vs placebo in postmenopausal women at increased risk of breast cancer.

international

3046

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

818

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

33

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

IBIS-II PUBLICATIONS

2023

Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial.

Cuzick J, Chu K, Keevil B, Brentnall AR, Howell A, Zdenkowski N, Bonanni B, Loibl S, Holli K, Evans DG, Cummings S, Dowsett M. The Lancet Oncology. 2023; epub 6 December 2023.https://doi.org/10.1016/S1470-2045(23)00578-8, E-pub

Impact of Baseline Oestradiol and Testosterone on the Preventive Effect of Anastrozole.

Cuzick J, Chu K, Keevil B, Howell A, Bonanni B, Gareth E, Holli K, Loibl S, Zdenkowski N, Cummings S. Dowsett M. SABCS 2023; PS10-03, Abstract

2021

The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies.

Smith SG, Sestak I, Morris MA, Harvie M, Howell A, Forbes J, Cuzick J. Breast Cancer Research and Treatment. 2021; epub 03 March 2021, https://doi.org/10.1007/s10549-021-06141-7, E-pub

Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial.

Sestak I, Blake G, Patel R, Cuzick J, Howell A, Coleman R, Eastell R. British Journal of Cancer 2021; epub 22 January 2021.https://doi.org/10.1038/s41416-020-01228-2: E-pub

2020

12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in situ.

Sestak I, Cuzick J, Bonanni B, Bundred N, Levy C, Loib S, Neven P, Stierer M, Holcombe C, Coleman R, Forbes J, Howell A. SABCS. 2020; GS2-02, Abstract

Carryover effects of aromatase inhibitors in prevention.

Chumsri S, Thompson EA. The Lancet. 2020; 395(10218):91-92, https://doi.org/10.1016/S0140-6736(19)33102-2, Commentary

LOAD MORE

Institutions